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Pure Bipolar Plasma Vaporization of the Prostate:
The Zu¨rich Experience
Benedikt Kranzbu¨hler, Marian Severin Wettstein, Christian D. Fankhauser, Nico C. Grossmann,
Oliver Gross, MD, Ce´dric Poyet, MD, Remo Largo, MD, Boris Fischer, MD, Matthias Zimmermann, MD,
Tullio Sulser, MD, Alexander Mu¨ller, MD, and Thomas Hermanns, MD
Introduction and Objectives: Bipolar plasma vaporization (BPV) has been introduced as an alternative to
transurethral resection of the prostate (TURP). Promising short-term results, but inferior mid-term results
compared to TURP have been reported following first-generation bipolar electrovaporization. Outcome data
following second-generation BPV are still scarce. The aim of this investigation was to evaluate the intra- and
postoperative outcomes of contemporary BPV in a center with long-standing expertise on laser vaporization of
the prostate.
Methods: A consecutive series of 83 patients undergoing BPV in a tertiary referral center was prospectively
evaluated. The investigated outcome parameters included the maximum flow rate (Qmax), postvoid residual
volume, International Prostate Symptom Score (IPSS)/quality of life (Qol), and prostate-specific antigen (PSA)
tests. Follow-up investigations took place after 6 weeks, 6 months, and 12 months. The Wilcoxon signed-rank
test was used to compare pre- and post-treatment parameters.
Results: The median (range) preoperative prostate volume was 41mL (17–111mL). The preoperative IPSS, Qol,
Qmax, and residual volume were 16 (2–35), 4 (0–6), 10.1mL/s (3–29.3mL/s), and 87mL (0–1000mL), respec-
tively. One third of the patients were undergoing platelet aggregation inhibition (PAI). No intraoperative
complications occurred. Postoperatively, 13 patients (15.7%) had to be recatheterized. Three patients (3.6%) had
clot retention and 28 patients (34%) reported any grade of dysuria. After 6 weeks, all outcome parameters
improved significantly and remained improved over the 12-month observation period [IPSS: 3 (0–2); Qol: 1 (0–4);
Qmax: 17.2mL/s (3.2–56mL/s); residual volume 11mL (0–190mL)]. The PSA reduction was 60% at study
conclusion. Three patients (3.6%) developed a urethral stricture and four patients (4.8%) bladder neck sclerosis.
Re-resections were not necessary.
Conclusions: Contemporary BPV is a safe and efficacious treatment option even for patients undergoing PAI.
Early urinary retention and temporary dysuria seem to be specific side effects of the treatment. Bleeding com-
plications are rare. Long-term follow-up is needed to confirm these promising short-term results.
Introduction
Monopolar transurethral resection of the prostate(TURP) has been shown to be an efficacious and du-
rable treatment option for patients with lower urinary tract
symptoms caused by prostatic enlargement.1–3 It is consid-
ered the surgical reference standard for patients with a pros-
tate volume of less than 80mL.4 However, despite many
technical refinements over the last decades, it is still associated
with a relevant rate of complications mainly caused by
bleeding and the so-called TUR syndrome.2,5,6 The morbidity
of TURP and the growing number of patients with significant
cardiovascular comorbidities orwith an imperative indication
for platelet aggregation inhibition (PAI) or anticoagulation
prompted the development of novel, minimally invasive al-
ternatives.
Bipolar TURP and 532 nm laser vaporization are two safe
and efficacious minimally invasive treatment options. They
both are characterized by improved hemostatic properties
and the possibility to perform intraoperative irrigation with
isotonic saline. A lower rate of bleeding complications com-
pared to conventional TURP and excellent clinical outcomes
have been reported for these procedures.7–9 Prostate vapor-
ization using the 532 nm laser is even safe in patients under-
going PAI or anticoagulation.10
Bipolar plasma vaporization (BPV) of the prostate has been
introduced to further improve the hemostatic properties of
bipolar TURP. Contemporary BPV using a hemispherical
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vaporization electrode combines the advantages of the bipo-
lar technique (affordable equipment, saline irrigation) with
the benefits of the 532 nm laser technique (tissue vaporization,
reduced bleeding, excellent overview, and short learning
curve). However, outcome data following contemporary BPV
of the prostate are still scarce. Initial reports are very prom-
ising with low intra- and perioperative morbidity and func-
tional short-term results comparable or even superior to
TURP.11–13 The aim of the present investigation was to eval-
uate the intra-, peri-, and postoperative outcomes of the initial
BPV series of our center, which has a long-standing expertise
on prostate vaporization using the 532 nm laser.
Patients and Methods
A consecutive series of patients undergoing BPV for pros-
tatic bladder outlet obstruction in a tertiary referral center
betweenAugust 2009 andNovember 2011were prospectively
evaluated. Approval for this observational study was ob-
tained from the local ethics committee and all enrolled pa-
tients provided written informed consent.
The attending urologist generally made the indication for
BPV after unsuccessful medical treatment or if the patient had
refused medical therapy for his symptomatic prostatic blad-
der outlet obstruction. BPVwas offered to all patients without
PAI or anticoagulation, but also to those undergoing PAI.
Preoperatively, patients were asked to complete the Inter-
national Prostate Symptom Score (IPSS) and quality of life
(Qol) questionnaire. Transrectal ultrasound of the prostate,
uroflowmetry, and postvoid residual volume measurement
were performed. The preoperative blood work included a
prostate-specific antigen (PSA) test. Patients with a PSA value
> 4 ng/mL or a suspicious digital rectal examination under-
went BPV only if a preoperative prostate biopsy showed no
malignant results. Urinalysis and a urine culture were also
routinely performed.
All patients with a normal preoperative urine status re-
ceived intravenous single-shot antibiotic prophylaxis with
Trimethoprim–Sulfametoxazole 160/80mg 30–60 minutes
before the operation. In patients with significant leukocyturia,
antibiotic treatment was initiated preoperatively and contin-
ued for at least 5 days after catheter removal.
The procedure was carried out under either general or
spinal anesthesia. A SurgMaster UES-40 generator and the
hemispherical bipolar HF-vaporization electrode were used
in combination with a 24F OES continuous-flow Iglesias re-
sectoscope (all Olympus Winter & Ibe GmbH, Hamburg,
Germany). The power output used for tissue vaporization and
tissue coagulation was 290–320W and 150–170W, respec-
tively. The operation was performed using the vaporization
mode and coagulation was only used selectively for localized
bleeding. All procedures were carried out under continuous
low-pressure irrigation using an automated irrigation suction
pump (Endo Fluid Management System Urology, Future
Medical System SA, Gene`ve, Switzerland) and prewarmed
isotonic saline (37C).
The operation was carried out analogous to a conventional
TURP. After insertion of the cystoscope and careful inspection
of the prostate and bladder, the ureteral orifices were identi-
fied. Vaporization was initiated at the bladder neck to ablate
the median lobe of the prostate. The procedure was continued
at the lateral lobes. Finally, the anterior part of the prostate
and the apical/paracollicular region were vaporized until the
appearance of a TURP-like cavity. Extensive coagulation of
the cavity at the end of the operation was generally avoided.
In patients with a prostate volume of less than 30mL, an ad-
ditional bladder neck incision was regularly performed. At
the end of the procedures, a 20F three-way irrigation catheter
was inserted and continuous irrigation with isotonic saline
was initiated. The operative time (from insertion of the cys-
toscope to insertion of the catheter), the total amount of irri-
gation fluid, and all intraoperative complications were
recorded.
Generally, the catheter was removed after 3 days. In the
case of persisting hematuria, catheter removal was post-
poned. After removal of the catheter, uroflowmetry and
postvoid residual volume measurements were done. Perio-
perative complications, the duration of catheterization, and
recatheterizations were recorded.
The patients were regularly seen in follow-up after 6weeks,
6 months, and 12 months in the outpatient clinic. At each
follow-up visit, uroflowmetry, residual volume measure-
ments, and a PSA test were performed. Additionally, the IPSS
and Qol questionnaire were completed. Furthermore, the
patients were asked to report symptoms of dysuria.
All data are presented as median and range. Statistical
analysis was done using IBM SPSS Statistics software 20.0
(IBM, Armonk, NY). The preoperative variables were com-
pared to postoperative variables using the Wilcoxon signed-
rank test. All p-values < 0.05 were considered statistically
significant.
Results
A total of 83 patients were included in this study. The
preoperative patient characteristics are displayed in Table 1.
Twenty-six patients (31.3%) were operated under ongoing
Table 1. Baseline Patient Characteristics
Number of patients 83
Age (y) 67 (48–89)
Prostate volume (mL) 41 (17–111)
PSA (ng/mL) 2.69 (0.26–22.5)
IPSS 16 (2–35)
QoL 4 (0–6)
Qmax (mL/s) 10.1 (3–29.3)
Residual volume (mL) 87 (0–1000)
Indwelling catheter (n) 20 (24.1%)
ASA score 2 (1–3)
1 8 (9.6%)
2 50 (60.2%)
3 25 (30.1%)
Coagulation modifiers (n) 26 (31.3%)
Acetylsalicylic acid (n) 26 (31.3%)
Clopidrogel (n) 1 (1.2%)
Coumarin (n) 0 (0%)
Dual therapy (n) 1 (1.2%)
Positive urine culture (n) 32 (38.5%)
Indwelling catheter (n) 18 (21.6%)
No catheter (n) 14 (16.8%)
Data presented as median (range) or number (percent).
PSA=prostate-specific antigen; IPSS= International Prostate Symp-
tom score; QoL=quality of life; Qmax=maximum flow rate; ASA
score=American Society of Anesthesiology score.
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PAI with acetylsalicylic acid. One patient had dual PAI with
additional clopidrogel medication. In all six patients with oral
anticoagulation, the coumarin medication was periopera-
tively replaced by low molecular weight heparin at ther-
apeutical doses. Heparin was stopped 24 hours before the
operation and reinitiated with subtherapeutical doses after
the procedure. It was then gradually increased and replaced
by coumarin if no macrohematuria occurred.
All patients underwent the preoperative, initial postoper-
ative, and 6-week assessment. A total of 75 (90%) and 71 (86%)
patients were available for the evaluation after 6 and 12
months, respectively.
The intra- and perioperative results are shown in Table 2.
BPV was performed by a total of five surgeons. Three senior
surgeons did 67 procedures (81%) and two senior residents
did 16 supervised procedures (19%) in the form of a teaching
operation. Pure BPV was successfully completed in 82 pa-
tients (98.8%). Conversion to conventional bipolar TURP was
necessary in one patient with a prostate volume of 110mLdue
to intraoperative diffuse hemorrhage, which resulted in poor
visibility. The patient was not undergoing PAI, but was under
antibiotic therapy for an asymptomatic urinary tract infection.
Major intraoperative complications did not occur and intra- or
perioperative blood transfusions were not necessary in any of
the patients.
A total of 32 patients (36%) had a positive preoperative
urine culture. Nine of these patients had an unsuspicious urine
status. Postoperatively, a positive urine culture was found in
nine patients who subsequently were treated with antibiotics.
Only one of these patients had an indwelling catheter preop-
eratively. None of the patients developed symptoms of a sys-
temic urinary tract infection or an urosepsis.
Four of the 13 patients who needed postoperative re-
catheterization had an indwelling catheter preoperatively.
Three patients were discharged with a catheter of which, two
were successfully removed after 13 days. In one patient with
persistent urinary retention, a suprapubic cystostomy was
performed for a permanent solution. Perioperatively, one
patient developed gross hematuria with clot retention. Fol-
lowing cystoscopic clot evacuation, transurethral coagulation
of the ablation cavity was undertaken. One patient developed
a small bowel volvulus associated with an adhesive stran-
gulation 3 days after the operation. After laparotomy, a seg-
ment resection and enteroenterostomy were performed.
Seven days later an anastomotic leak was detected and a re-
vision of the enteroenteostomy was necessary. The patient
was discharged 36 days after BPV.
Table 3 summarizes the postoperative outcome parame-
ters. Themaximumflow rate (Qmax) and the residual volume
were already investigated after catheter removal. The Qmax
increased nonsignificantly to 14mL/s ( p = 0.06), whereas the
reduction of the residual volume was already statistically
significant at this early postoperative assessment ( p< 0.001).
After 6 weeks, all functional outcome parameters improved
significantly compared to the baseline values (Wilcoxon
p< 0.001 (IPPS, Qol, residual volume) and Wilcoxon p = 0.006
(Qmax)). A further significant improvement was detectable
after 6months for the IPSS andQol and after 12months for the
IPSS. All parameters remained significantly improved over
the entire 12-month observation period (Table 3). The PSA
value was already significantly reduced after 6 weeks
( p < 0.001). After 12months, a 60% reduction of the initial PSA
value was detectable (Table 3).
Table 4 illustrates further postoperative results. Of the 15
patients who were found to have a positive urine culture
6weeks after surgery, six had an indwelling catheter and ten a
positive urine culture preoperatively. All patients were trea-
ted with oral antibiotics. One patient was diagnosed with a
pyelonephritis 1 month after the operation. The urine was
found to be positive for mycobacterium tuberculosis. An ini-
tial four-drug regimen was followed by a three-drug treat-
ment for 9 months. Subsequently, mycobacteria were not
detectable anymore. Four patients were diagnosed with a
urinary tract infection between the 6-week and 6-month fol-
low-up. Afterward, urinary tract infections were not diag-
nosed anymore.
Two patients (2.4%) presented with delayed hematuria and
clot retention after 4 and 6 weeks, respectively. Both patients
were hospitalized for cystoscopic clot evacuation and subse-
quent coagulation. One of these patients was undergoing dual
Table 2. Intra- and Perioperative Results
Operative time (min) 80 (34–145)
Irrigation volume (l) 22.5 (12–39)
General anesthesia (n) 60 (72.2%)
Spinal anesthesia (n) 23 (27.8%)
Blood transfusion (n) 0 (0%)
Duration of catheterization (d) 3 (2–13)
Duration of hospitalization (d) 4 (2–11)
Recatheterization (n) 13 (15.6%)
Urinary retention (n) 10 (12%)
High residual volume +UTI (n) 2 (2.4%)
Clot retention (n) 1 (1.2%)
Data presented as median (range) or number (percent).
UTI=urinary tract infection.
Table 3. Baseline and Postoperative Outcome Parameters
Parameter Baseline Postoperative 6 weeks 6 months 12 months
IPSS 16 (2–35) N/A 8a (0–29) 3a,b (0–24) 3a,b (0–20)
QoL 4 (0–6) N/A 2a (0–6) 1a,b (0–4) 1a (0–4)
Qmax (mL/s) 10.1 (3–29.3) 14.0 (3.8–47) 16.7a (2.3–52) 16.7a (5–53.8) 17.2a (3.3–56)
Residual volume (mL) 87 (0–1000) 20a (0–900) 10a (0–437) 6.5a (0–500) 11a (0–190)
PSA (ng/mL) 2.69 (0.26–22.5) N/A 1.36a (0.04–9.56) 1.27a (0.15–6.98) 1.11a (0.08–7.18)
Data presented as median (range).
aIndicates a statistically significant improvement compared to the baseline value (Wilcoxon signed-rank test).
bIndicates a statistically significant improvement compared to the preceding assessment (Wilcoxon signed-rank test).
N/A=not applicable.
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PAI medication, and therefore laser coagulation of the abla-
tion cavity was performed. In three symptomatic patients
(4%), a de novo urethral stricturewas diagnosed and treated by
visual internal urethrotomy after 6 and 8 months and by a
simple dilatation procedure after 11 months, respectively. All
of the four patients who developed a symptomatic bladder
neck sclerosis were treated by transurethral bladder neck in-
cision after 2 months (n = 1) 4 months (n = 2) and 7 months
(n = 1), respectively. Only one of the patients had an initial
prostate volume of less than 30mL and none of the patients
had a urinary tract infection pre- or postoperatively.
Discussion
This prospective investigation of intra-, peri-, and postop-
erative outcomes following pure contemporary BPV of the
prostate revealed that the procedure is safe, has a low mor-
bidity, and results in significant improvements of all investi-
gated outcome parameters. No major intraoperative
complications occurred and conversion to conventional bipolar
transurethral resectionwas necessary in only one patientwith a
large prostate. Postoperative bleeding complications, which
required reinterventions but no transfusions, occurred in three
patients of whom one was undergoing dual PAI. Interestingly,
two of these complications occurred with a delay of 4 to 6
weeks after the operation. Urinary tract infections were rela-
tively frequent preoperatively, but also in the early postoper-
ative period. One third of the patients reported dysuria after 6
weeks. After 6 months, urinary symptoms were generally rare.
Reoperations due to persistent obstructive tissue were not
necessary, but seven patients (8%) were treated for symptom-
atic urethral strictures (n= 3) or bladder neck sclerosis (n= 4).
Kaplan and Te introduced electrovaporization of the
prostate using a rollerball electrode in 1995.14 Despite prom-
ising functional results, this monopolar technique was soon
abandoned due to higher rates of irritative voiding symptoms
and stress urinary incontinence compared to conventional
TURP.11,15 In 2001, Botto and colleagues reported their initial
results of a bipolar vaporization technique using a special bar
electrode.16 Subsequently, several studies revealed a lower
intra- and perioperative morbidity and functional short-term
results comparable to conventional TURP.17–20 However,
midterm results have been reported to be inferior compared to
TURP.7,21
In 2008, a novel bipolar device using an ergonomic, hemi-
spherical electrode and a different energy setting was laun-
ched.22 To date, only limited data are available for this
contemporary BPV technique. In 2010, Reich and colleagues
reported their initial clinical experience of a very small series
of 30 patients with a follow-up of 6 months.11 Four different
surgeons from two centers did the operations. Their short-
term functional results were comparable to the results of the
present study. Bleeding complications did not occur and one
patient with a large initial prostate volume required re-
operation 4 weeks after the initial procedure.
Robert and colleagues reported a French multicenter ob-
servational study of 106 consecutive patients with a short-
term follow-up of 3 months.13 Patients were recruited from
eight different centers. A maximum of three surgeons per
center performed the operations resulting in an average of
only seven operations per surgeon. Improvements of the IPSS
and bother score were comparable to the improvements ob-
served in the present study. However, a high failure rate of
eight percent after 3 months indicates that tissue ablation
might have been insufficient in a relevant proportion of pa-
tients in this study. Additionally, three major complications
(urethral necrosis with urinary fistulas (n = 2) and significant
bladder necrosis (n= 1)) occurred in three consecutive patients
from one center. These complications were considered to be
associated with material failure. The case of a small bowel
volvulus requiring a segment resection represents a serious
complication in our series. It is likely that the development of
the volvulus is somehow related to the initial surgery. How-
ever, we do not believe that this complication is specifically
related to the BPV procedure.
The same group from France reported a post hoc retro-
spective comparison of 54 patients under oral anticoagulation
from their initial study and 57 patients undergoing TURP
under oral anticoagulation.23 Comparable functional results
after 3 months, but significantly less bleeding complications
after BPVwere seen. It is noteworthy that most of the patients
were not under oral anticoagulation but under PAI. Further-
more, PAI was stopped in themajority of the patients and oral
anticoagulation was replaced by heparin in all patients before
surgery. In the present investigation, 30% of the patients were
under ongoing PAI. Intraoperative bleeding complications
did not occur in these patients. However, dual PAI and uri-
nary tract infections might increase the risk of intra- and
perioperative bleeding complications.
Two randomized trials comparing BPV with monopolar
and bipolar TURP were conducted by Geavlete and col-
leagues.12,24 In their first study, they reported the 6-month
results of 155 patients undergoing either BPV (n = 75) or
monopolar TURP (n = 80) done by a single surgeon.24 The
operative time, catheterization period, and hospital stay were
significantly shorter in the BPV arm. Furthermore, all relevant
outcome parameters were in favor of BPV and the complica-
tion rate was significantly lower following BPV compared to
TURP. The mean operative time was 35.1 minutes and the
mean prostate volume decreased from 56.2 to 16.8mL after 6
months. Compared to the present investigation, the Qmax in
their study was slightly higher and the recatheterization rate
and dysuria rate lower. Urethral strictures and reoperations
were not reported.
The second trial by the same group indicated to evaluate
long-term results of a randomized trial of 510 patients who
underwent BPV (n = 170), monopolar TURP (n = 170), and bi-
polar TURP (n = 170).12 However, with a follow-up of only 18
Table 4. Postoperative Results
Urinary tract infection
£ 6 weeks (n) 15 (18%)
6 weeks–6 months (n) 4 (4.8%)
6 months–12 months (n) 0 (0%)
Delayed clot retention (£ 6 weeks; n) 2 (2.4%)
Dysuria
6 weeks (n) 28 (34%)
6 months (n) 2 (2.4%)
12 months (n) 3 (3.6%)
Urethral stricture (n) 3 (3.6%)
Bladder neck sclerosis (n) 4 (4.8%)
Re-resection (n) 0 (0%)
Data presented as median (range) or number (percent).
1264 KRANZBU¨HLER ET AL.
months, we think that the results of this trial represent rather
short-term than long-term results. This large-scale single
center trial revealed a clear benefit for BPV in terms of com-
plications and clinical outcome. The intraoperative compli-
cation rate was significantly lower in the BPV arm compared
to both, the monopolar and the bipolar TURP arm. Post-
operative irritative voiding symptoms and urethral strictures
were comparable between the three groups. However, a sig-
nificantly lower recatheterization rate, a lower rate of bladder
neck sclerosis, and fewer retreatments were detectable fol-
lowing BPV. Furthermore, improvements of IPSS, Qol, and
Qmax were significantly better in the BPV arm. It remains
unclear why the bipolar TURP arm and the additional 95 and
90 patients in the BPV and monopolar TURP arm, respec-
tively, were not reported in the initial series that was pub-
lished only 12 months earlier. Long-term follow-up will show
if these excellent results are durable.
In the present study the duration of catheterization was
significantly longer compared to the other studies.11,13,24 This
difference is not related to a higher rate of bleeding compli-
cations, but is mainly due to local reimbursement policies
in Switzerland. The present investigation also revealed a
lower Qmax compared to the studies by Geavlete and col-
leagues.12,24 The improvement of the Qmax in the present
investigation is comparable to what has been reported in the
studies by Reich and Robert, respectively.11,13 However, it
seems also to be significantly lower than the improvement
reported following monopolar TURP.7,24 All other investi-
gated functional outcome parameters are comparable to the
results reported after BPV and monopolar TURP. The studies
of Geavlete and colleagues also showed a lower complication
rate compared to the present investigation. We found more
urinary tract infections, recatheterizations, and higher rates of
dysuria and bladder neck sclerosis. Dysuria, early postoper-
ative urinary retention, and urinary tract infections have been
reported to be frequent after 532 nm laser vaporization of the
prostate.7 The higher rate of these complications in the present
study might indicate that these complications are associated
with prostate vaporization in general. Given thewide range of
the reported rate of bladder neck sclerosis following BPV
among different studies (0.6% to 7.2%), the rate in the present
study appears to be rather average.12,25 Furthermore, it seems
to be comparable to what has been reported for monopolar
and bipolar TURP.26,27 In our collective, retreatments were
not necessary during the 12-month observation period. This is
lower compared to published BPV and TURP data. A longer
follow-up has to confirm this promising result.
The generally excellent coagulation properties of the bi-
polar vaporization device result in an excellent overview
during the procedure and, in our opinion,make this treatment
modality particularly appealing for teaching operations.
However, we also realized that the procedure has to be per-
formed in a speedy manner to achieve sufficient tissue abla-
tion in a reasonable time. The experience of the surgeon is
likely to influence the speed and efficiency of tissue vapor-
ization during BPV. In the study by Geavlete, a single surgeon
did all the procedures. This might explain the excellent abla-
tion rate of approximately 40mL in 35 minutes and the above
average clinical outcome.24 The high retreatment rate in the
French study might reflect the insufficient tissue ablation of
surgeons, who were rather inexperienced using this tech-
nique.13 All senior surgeons in the present study were expe-
rienced in prostate vaporizations using the 532 nm laser. This
experience might improve the vaporization efficiency partic-
ularly in the learning phase of the BPV procedure. The PSA
reduction of 60% and the lack of necessity for reoperations
substantiate this assumption.
A drawback of the present investigation is the lack of a
control group, which limits the ability to compare the results
with those of other techniques. However, given the sparsely
available data of contemporary BPV, our study adds impor-
tant information to the published evidence. Furthermore, we
did not design and power this study for subgroup analyses,
which might allow identifying predictors of clinical outcome
following BPV. A larger prospective investigation would be
required to formally identify these predictors and our results
can be helpful in designing such a study. The long-standing
experience with prostate vaporization techniques in our cen-
ter, the longer follow-up period, the larger number of patients,
and the lower number of surgeons who performed the pro-
cedure compared to most of the other BPV studies are specific
advantages of our investigation.
Conclusion
Contemporary BPV is a safe and efficacious treatment
option even for patients undergoing PAI. BPV results in sig-
nificant improvements of all relevant outcome parameters
over a 12-month period. Bleeding complications are rare.
Early urinary retention and temporary dysuria seem to be
specific side effects of the treatment. A multi-institutional
study with long-term follow-up is needed to confirm the
promising short-term results and to further evaluate the du-
rability of the procedure.
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BPV¼ bipolar plasma vaporization
IPSS¼ International Prostate Symptom Score
PAI¼platelet aggregation inhibition
PSA¼prostate-specific antigen
Qmax¼maximum urinary flow rate
Qol¼ quality of life
TURP¼ transurethral resection of the prostate
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